Robert Orlowski

Dr. Robert Orlowski, the Principal Investigator of this proposal, serves as the Florence Maude Thomas Cancer Research Professor and Director of the Myeloma Section at The University of Texas MD Anderson Cancer Center, and is the Deputy Chair of the Department of Lymphoma & Myeloma. Also, Dr. Orlowski serves as the Chair of the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network that conducts studies to advance novel therapies for myeloma, and to expand our understanding of its biology. In the laboratory arena, Dr. Orlowski is a physician scientist whose focus has been on bench-to-bedside research that develops and validates novel therapies to improve patient outcomes, and focuses on drug resistance mechanisms that may serve as predictive biomarkers for response. His past work has included leading roles in the development of the proteasome inhibitors bortezomib and carfilzomib, as well as the monoclonal antibodies daratumumab and elotuzumab.